Appl. No.: Unassigned Filing Date: Herewith

## Amendments to th Claims:

This listing of claims will replace all prior version, and listings of claims in this application.

Claims 1-28 (Cancelled)

Claim 29 (Currently Amended) A method of transfecting polynucleotedes into cells in vivo for gene therapy, which method comprises administering peptide-based gemini compounds of any of of claims 1 to 20 a peptide-based gemini compound according to the formula (I):

where:

A<sup>1</sup> and A<sup>5</sup>, which may be the same or different, are positively charged groups formed from one or more amino acids or amines joined together in a linear or branched manner;

A<sup>2</sup> is the side chain of an amino acid;

A<sup>6</sup> is the side chain of an amino acid,

p and q, which may be the same or different, is 0 or 1;

X<sup>1</sup> is O or S;

 $X^2$  is O or S;

A<sup>4</sup> is CH<sub>2</sub>OH or CH(CH<sub>3</sub>)OH;

A<sup>8</sup> is CH<sub>2</sub>OH or CH(CH<sub>3</sub>)OH;

Y is a linker group, or when each of  $X^1$  and  $X^2$  is S, the group of variables  $X^1$ -Y- $X^2$  taken together represents a disulfide bond;

R<sup>1</sup> and R<sup>2</sup> are C<sub>(10-20)</sub> saturated or unsaturated alkyl groups, and

· Appl. No.: Unassigned Filing Date: Herewith

W and Z are NH, O, CH2 or S; or

a salt thereof,

together with, or separately from, a the gene therapy vector.

Claim 30 (Cancelled)

Claim 31 (Cancelled)

32. (Currently Amended) A process for preparing peptide-based gemini compounds of claim 1 or 2 according to formula (I):

where:

A<sup>1</sup> and A<sup>5</sup>, which may be the same or different, are positively charged groups formed from one or more amino acids or amines joined together in a linear or branched manner;

A<sup>2</sup> is the side chain of an amino acid;

A<sup>6</sup> is the side chain of an amino acid;

p and q, which may be the same or different, is 0 or 1;

X<sup>1</sup> is O or S;

 $X^2$  is O or S;

A<sup>4</sup> is CH<sub>2</sub>OH or CH(CH<sub>3</sub>)OH;

A<sup>8</sup> is CH<sub>2</sub>OH or CH(CH<sub>3</sub>)OH;

Y is a linker group, or when each of  $X^1$  and  $X^2$  is S, the group of variables  $X^1-Y-$ 

X<sup>2</sup> taken together represents a disulfide bond;

R1 and R2 are C(10-20) saturated or unsaturated alkyl groups, and

\*Appl. No.: Unassigned Filing Date: Herewith

## W and Z are NH, O, CH2 or S; or

## a salt thereof,

which process comprises adding amino acids or peptides to 2-amino-3-{2-[2-amino-2-(1-dodecylcarbamoyl-2-hydroxy-ethylcarbamoyl)-ethylsulphanyl]-ethylsulphonyl}-N-(1-dodecylcarbamoyl-2-hydroxy-ethyl-) propionamide.